-
Drugs 1988In this randomised, double-blind, crossover trial, the efficacy in hypertension of atenolol and nifedipine as single agents or in combination was compared. 81 patients... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
In this randomised, double-blind, crossover trial, the efficacy in hypertension of atenolol and nifedipine as single agents or in combination was compared. 81 patients with mild to moderate essential hypertension (sitting diastolic blood pressure 100-120 mm Hg, aged 20-70 years) from 6 outpatient clinics entered the study. By use of a Latin-square design, patients received, in randomised fashion, sustained release nifedipine 20mg twice daily, atenolol 50mg in the morning and then placebo in the evening, or sustained release nifedipine 20mg plus atenolol 50mg in the morning and then placebo in the evening. Each schedule was followed for 4 weeks. All treatments lowered systolic and diastolic blood pressure in the supine and standing positions compared with pretreatment values. The combination regimen significantly reduced supine and standing systolic (p less than 0.01 and p less than 0.001, respectively) and diastolic (p less than 0.001) blood pressure compared with nifedipine alone, and it also significantly reduced supine and standing systolic (p less than 0.01 and p less than 0.03, respectively) and diastolic (p less than 0.01) blood pressure compared with atenolol alone. Heart rate was significantly decreased by atenolol and the combination compared with nifedipine alone. 15 patients withdrew because of side effects: 9 during nifedipine treatment, 2 during atenolol treatment and 4 during combination treatment. Side effects were typical of those associated with nifedipine or atenolol. Flushes and hot sweats, which were frequent with nifedipine, were significantly less (p less than 0.001) with atenolol or the combination.(ABSTRACT TRUNCATED AT 250 WORDS)
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nifedipine; Random Allocation
PubMed: 3288467
DOI: 10.2165/00003495-198800354-00006 -
Clinical Science and Molecular... Dec 19761. Atenolol (ICI 66.082, Tenormin) is a new beta-adrenoreceptor-blocking agent, devoid of intrinsic sympathomimetic and membrane-stabilizing properties. It does not... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
1. Atenolol (ICI 66.082, Tenormin) is a new beta-adrenoreceptor-blocking agent, devoid of intrinsic sympathomimetic and membrane-stabilizing properties. It does not cross the blood-brain barrier. 2. Atenolol given to hypertensive patients in initial open trials reduced arterial blood pressure significantly. 3. A double-blind comparison between atenolol and placebo in forty-five patients with essential hypertension demonstrated that atenolol gave a statistically significant reduction of blood pressure (delta 28/15 mmHg, P less than 0-005). 4. The optimum anti-hypertensive dose of atenolol in patients with mild to moderately severe essential hypertension was 200 mg daily. 5. Atenolol was compared with propranolol in thirty patients with essential hypertension. No statistically significant differences of anti-hypertensive effect were observed between the two drugs. 6. Long-term results (up to 2 years) in 117 hypertensive patients indicate that drug tolerance is good. No serious toxic effects were observed. 7. In four of twelve hypertensive patients with obstructive airways disease atenolol had to be withdrawn owing to deterioration of ventilatory function.
Topics: Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Lung Diseases, Obstructive; Propanolamines; Propranolol
PubMed: 799559
DOI: 10.1042/cs051513s -
European Journal of Clinical... Nov 1977The pharmacokinetics of atenolol, a new cardioselective beta-adrenoceptor blocking agent, were determined following both acute and chronic dosing in 33 hypertensive...
The pharmacokinetics of atenolol, a new cardioselective beta-adrenoceptor blocking agent, were determined following both acute and chronic dosing in 33 hypertensive patients with widely differing levels of renal impairment. In patients with normal renal function the atenolol half-life was calculated to be about six hours following single 100 mg oral doses. This value increased markedly in patients with renal insufficiency and the blood clearance of atenolol was found to have a significant correlation with the glomerular filtration rate. This demonstrated the importance of the kidneys in the elimination of the drug. After 8 weeks oral treatment with atenolol (100 mg twice daily) a significant decrease in blood pressure, heart rate and plasma renin activity was observed, but no correlation was established between the blood levels of atenolol and any of its pharmacodynamic effects. A positive correlation was found however between the anti-hypertensive action of atenolol and the pretreatment value of the plasma renin activity.
Topics: Atenolol; Blood Pressure; Heart Rate; Humans; Hypertension; Kidney Diseases; Kinetics; Propanolamines; Renin; Time Factors
PubMed: 590303
DOI: 10.1007/BF00609856 -
BMJ (Clinical Research Ed.) Mar 1993
Topics: Atenolol; England; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Risk Factors
PubMed: 8461813
DOI: 10.1136/bmj.306.6878.622 -
Polski Merkuriusz Lekarski : Organ... Dec 1996It is well known that beta-2-blockers are contraindicated for patients with bronchial hyperactivity. Author discusses the clinical observations in relation to treatment... (Review)
Review
It is well known that beta-2-blockers are contraindicated for patients with bronchial hyperactivity. Author discusses the clinical observations in relation to treatment with atenolol in circulatory system pathology.
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Atenolol; Cardiovascular Diseases; Coronary Disease; Humans; Hypertension
PubMed: 9273241
DOI: No ID Found -
Hemodialysis International.... Oct 2013Owing to the drug's favorable hydrophilic and pharmacokinetic characteristics, a number of case reports have demonstrated effective treatment of atenolol overdose with...
Owing to the drug's favorable hydrophilic and pharmacokinetic characteristics, a number of case reports have demonstrated effective treatment of atenolol overdose with hemodialysis. However, the efficiency of atenolol clearance throughout hemodialysis treatments has not previously been examined. In this report, a patient with impaired renal function was successfully treated with two 5-hour intermittent high-flux high-efficiency hemodialysis therapies after atenolol overdose. Serial atenolol levels were measured during his hemodialysis treatments. We observed an over 50% plasma atenolol concentration reduction after each 5-hour hemodialysis therapy. Hemodialysis therapy is an effective treatment for atenolol overdose, especially in patients with impaired renal function.
Topics: Atenolol; Drug Overdose; Humans; Male; Middle Aged; Renal Dialysis; Renal Insufficiency
PubMed: 23347063
DOI: 10.1111/hdi.12020 -
Lancet (London, England)
Topics: Atenolol; Colonic Diseases, Functional; Humans
PubMed: 2891937
DOI: 10.1016/s0140-6736(88)91056-2 -
Deutsche Medizinische Wochenschrift... Jun 1987
Topics: Alcoholic Intoxication; Atenolol; Diazepam; Female; Humans
PubMed: 3582207
DOI: No ID Found -
The American Journal of Cardiology Sep 1986To determine the efficacy and safety of intravenous atenolol in patients with frequent and repetitive benign or potentially lethal ventricular arrhythmias, 40 patients... (Clinical Trial)
Clinical Trial
To determine the efficacy and safety of intravenous atenolol in patients with frequent and repetitive benign or potentially lethal ventricular arrhythmias, 40 patients received an open-label, single dose of 10 mg of intravenous atenolol, given in aliquots of 2.5 mg every 10 minutes. Twenty-four-hour Holter monitoring was performed on the day before, the day of, and the day after infusion of atenolol. A full 10-mg dose was given to 37 patients; asymptomatic bradycardia developed in 3 patients, and they were not included in the efficacy analysis. A single 10-mg dose of intravenous atenolol was effective rapidly in suppressing ventricular arrhythmias, with peak suppression occurring 1 to 2 hours after infusion and significant suppression lasting for 7 hours. Only 1 patient had symptoms (lightheadedness), plus hypotension lasting 45 minutes after the infusion was concluded. The mean plasma level of atenolol was 231 ng/ml 10 minutes after the infusion, with individual patient values of 148 to 457 ng/ml. Thus, a single intravenous dose of 10 mg of atenolol can significantly reduce the frequency of ventricular premature complexes and ventricular tachycardia within the first hour after infusion; suppression can last for 7 hours. Atenolol is well tolerated.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Clinical Trials as Topic; Electrocardiography; Heart Ventricles; Humans; Injections, Intravenous; Middle Aged; Time Factors
PubMed: 3529912
DOI: 10.1016/0002-9149(86)90023-8 -
The British Journal of Ophthalmology May 1977Guttae atenolol 4% (Tenormin), a pure beta1-blocking (i.e., cardioselective) drug, produced a median overall fall of 5-6 mmHg (range 3-2 to 13-2 mmHg) in the first... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
Guttae atenolol 4% (Tenormin), a pure beta1-blocking (i.e., cardioselective) drug, produced a median overall fall of 5-6 mmHg (range 3-2 to 13-2 mmHg) in the first tonometrised eyes of 7 patients with open-angle glaucoma or ocular hypertension and 1 with closed-angle glaucoma (off any treatment for the whole of the day preceding each test day) after allowance for an 'effect' of guttae saline 0-9%, in a double-masked, cross-over trial. By a Wilcoxon matched pairs rank test this was significant at the P less than 0-05 level. The median overall fall of 3-5 mmHg (range 0-8 to 10-8 mmHg) in the second-tonometrised eyes of 7 patients (1 of the 8 contributed only 1 eye) was also significant (P less than 0-05). In 2 patients who had been treated with guttae atenolol 4% daily 3 X for 1 and 2 months there is evidence that, on replacing the atenolol 4% with saline 0-9%, a rise of pressure of around 3 mmHg occurred 2 and 3 and 5 days later, i.e., the drug still retained its effectivity (slightly reduced) after 1 and 2 months.
Topics: Atenolol; Clinical Trials as Topic; Glaucoma; Humans; Intraocular Pressure; Propanolamines; Tonometry, Ocular
PubMed: 326303
DOI: 10.1136/bjo.61.5.349